Lidan Sun

Shenzhen 518060, PR China
Puerto Rico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Nanoconfinement and tandem catalysis over yolk-shell catalysts towards electrochemical reduction of CO2 to multi-carbon products.

Nanoconfinement and tandem catalysis over yolk-shell catalysts towards electrochemical reduction of CO2 to multi-carbon products.

Journal: Journal of colloid and interface science

Published: November 21, 2024

Evolution and therapeutic potential of glucagon-like peptide 2 analogs.

Evolution and therapeutic potential of glucagon-like peptide 2 analogs.

Journal: Biochemical pharmacology

Published: August 22, 2024

Discovery of the FXR/CES2 dual modulator LE-77 for the treatment of irinotecan-induced delayed diarrhea.

Discovery of the FXR/CES2 dual modulator LE-77 for the treatment of irinotecan-induced delayed diarrhea.

Journal: Bioorganic chemistry

Published: August 12, 2024

Enhancing electron interaction between Pt and support for superior electrochemical performance through atomic layer deposition of tungsten oxide.

Enhancing electron interaction between Pt and support for superior electrochemical performance through atomic layer deposition of tungsten oxide.

Journal: Journal of colloid and interface science

Published: September 11, 2023

Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.

Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.

Journal: Bioorganic & medicinal chemistry

Published: August 18, 2023

Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.

Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.

Journal: Biochemical pharmacology

Published: June 24, 2023

Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.

Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.

Journal: Peptides

Published: November 06, 2022

A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes.

A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes.

Journal: British journal of pharmacology

Published: July 28, 2021

Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.

Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.

Journal: Molecular pharmaceutics

Published: July 09, 2021

Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.

Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.

Journal: Bioorganic & medicinal chemistry

Published: July 06, 2019

Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.

Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.

Journal: Bioorganic chemistry

Published: May 16, 2019

Novel nonapeptide GLP (28-36) amide derivatives with improved hypoglycemic and body weight lowering effects.

Novel nonapeptide GLP (28-36) amide derivatives with improved hypoglycemic and body weight lowering effects.

Journal: Bioorganic & medicinal chemistry

Published: February 07, 2019

Showing 1-12 of 28

Last Updated: 09/26/2026